Marksans Pharma Limited

Marksans Pharma Limited (MARKSANS) is a small-cap Healthcare company valued at ₹14,093 crore operating in Pharmaceuticals on the NSE and BSE.

Recent price move

Marksans Pharma Limited last traded at ₹311, modestly up 1.02% on the day.

Recent developments

On 2026-07-08, the company announced plans to acquire a German pharmaceutical company, which will enhance its sales, marketing, and distribution capabilities in the German healthcare market.

Financial performance

The company's annual revenue rose 12.5% to ₹2,951 crore, while annual net profit increased 9.7% to ₹420 crore. The latest quarter saw revenue jump 35.6% to ₹841 crore and net profit surge 174.8% to ₹159 crore, outpacing the same quarter a year earlier. However, the net profit margin narrowed 0.4 percentage points to 14.2%, and return on equity remained flat at 13.8%.

Valuation multiples

The stock trades at 33.7 times earnings, broadly in line with the Healthcare median of 32.0, 4.95 times book value. It yields 0.3%.

Things to watch

The stock is 7.2% below its 52-week high, and the net profit margin has narrowed by 0.4 percentage points. Promoter holding remained at 43.87%, while domestic institutional holding decreased by 0.38 points in the quarter.

Where it stands

The company has shown strong revenue and profit growth over the past year and quarter, with revenue rising 12.5% and net profit increasing 9.7% annually. The latest quarter saw a significant jump in both revenue and net profit, with the latter rising 174.8%. The stock is currently 7.2% below its 52-week high, and the net profit margin has narrowed slightly.

Summarised by DocStoX's model on 2026-10-03 from company filings, exchange data and news. This is a factual summary, not a rating or a recommendation. Informational only, not investment advice. Consult a SEBI-registered adviser before investing.